SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that President and CEO Theodore Schroeder will present a corporate overview on Wednesday, June 13, 2007 at 9:30am Eastern Time (6:30am Pacific Time) during the Sixth Annual Needham & Company, LLC Biotechnology & Medical Technology Conference at the New York Palace Hotel in New York City.
The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals’ website at http://www.cadencepharm.com. To access the presentation, click on the Investor Relations tab and then click on the link entitled “Events and Presentations” on the left side of the screen. A replay of the webcast will available approximately one hour after the live webcast concludes and will be archived for 30 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, including IV APAP (acetaminophen for injection) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence’s pipeline, visit http://www.cadencepharm.com.
Forward-Looking Statements
Cadence cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cadence’s business including, without limitation, the progress and timing of the company’s ongoing and planned clinical trials, difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products and other risks detailed in Cadence’s prior press releases as well as in Cadence’s public filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Contacts: William R. LaRue Susan Neath SVP & Chief Financial Officer Media & Investor Relations Cadence Pharmaceuticals, Inc. Porter Novelli Life Sciences 858-436-1400 (619) 849-6007
Cadence Pharmaceuticals, Inc.
CONTACT: William R. LaRue, SVP & Chief Financial Officer of CadencePharmaceuticals, Inc., +1-858-436-1400; or Media & Investor Relations,Susan Neath of Porter Novelli Life Sciences, +1-619-849-6007, for CadencePharmaceuticals, Inc.
Web site: http://www.cadencepharm.com/
